Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Description: The monoclonal antibody eBio28F12 reacts with and inhibits the bioactivity of mouse TSLP. Thymic Stromal-Derived Lymphopoetin (TSLP) was first identified in the tissue culture supernatant of a thymic stromal cell line as a growth factor capable of inducing proliferation and differentiation of pre-B cells. It was later found to be closely related to another stromal cytokine, IL-7, with which it shares overlapping functions. Along with its proliferative effects on B cells, TSLP induces dendritic cells to support the differentiation of naive T cells towards the Th2 lineage and may also be involved in the development of CD4^+CD25^+ regulatory T cells. The receptor for TSLP is heterodimeric and shares one subunit, IL-7Ralpha, with IL-7 and other members of the family, while the TSLPR subunit is unique to TSLP.
TSLP expression can be induced by a variety of inflammatory cytokines and TLR ligands. Expression is regulated by NF-kappaB and has been detected in epithelial cells, stromal cells, and basophils. Elevated levels of TSLP are associated with asthma and atopic dermatitis, which are both Th2-mediated inflammatory conditions. It is believed that chronic overexpression of TSLP may result in increased sensitivity to allergens, resulting in susceptibility to these conditions.
Applications Reported: The monoclonal antibody eBio28F12 reacts with and inhibits the bioactivity of mouse TSLP.
Applications Tested: The ND50 of eBio28F12, as determined by the neutralization of recombinant mouse TSLP-induced proliferation of the Nag8/7 cell line, is 1-3 ng/mL in the presence of 0.5 ng/mL mTSLP. The neutralization dose of this antibody will vary depending on cell type, assay method, and cytokine concentration.
Storage and handling: Use in a sterile environment.
Filtration: 0.2 µm post-manufacturing filtered.
Purity: Greater than 90%, as determined by SDS-PAGE.
Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay.
Aggregation: Less than 10%, as determined by HPLC.
TSLP is a 159 amino acid four helix-bundle hemopoietic cytokine that signals through a heterodimeric receptor complex consisting of the human TSLP receptor and the IL-7R alpha-chain. It impacts myeloid cells and induces the release of T cell-attracting chemokines from monocytes, enhances the maturation of CD11c (+) dendritic cells, naive CD4 (+), and CD8 (+) T cells into proallergic effectors, and primes dendritic cells to produce large amounts of IL-12 after CD40 ligand stimulation. TSLP influences the regulation of the positive selection of regulatory T cells and maintenance of peripheral CD4 (+) T cell homeostasis. It induces allergic inflammation by directly activating mast cells and may be involved in the pathophysiology of inflammatory arthritis. It is expressed in heart, liver and prostate.
仅用于科研。不用于诊断过程。未经明确授权不得转售。